Last Update 20:30
Sunday, 23 September 2018

Scientists unpick how cannabis component may fight psychosis

The ingredient could become a novel anti-psychotic medicine.

Reuters , Thursday 30 Aug 2018
Reuters
Share/Bookmark
Views: 1933
Share/Bookmark
Views: 1933

British scientists have unraveled how a non-intoxicating component of cannabis acts in key brain areas to reduce abnormal activity in patients at risk of psychosis, suggesting the ingredient could become a novel anti-psychotic medicine

While regular use of potent forms of cannabis can increase the chances of developing psychosis, the chemical cannabidiol or CBD appears to have the opposite effect.

CBD is the same cannabis compound that has also shown benefits in epilepsy, leading in June to the first U.S. approval of a cannabis-based drug, a purified form of CBD from GW Pharmaceuticals. 

Previous research at King’s College London had shown that CBD seemed to counter the effects of tetrahydrocannabinol or THC, the substance in cannabis that makes people high. But how this happened was a mystery.

Now, by scanning the brains of 33 young people who were experiencing distressing psychotic symptoms but had not been diagnosed with full-blown psychosis, Sagnik Bhattacharyya and colleagues showed that giving CBD capsules reduced abnormal activity in the striatum, medial temporal cortex and midbrain.

Abnormalities in all three of these brain regions have been linked to the onset of psychotic disorders such as schizophrenia.

Most current anti-psychotic drugs target the dopamine chemical signaling system in the brain, while CBD works in a different way.

Significantly, the compound is very well tolerated, avoiding the adverse side effects such as weight gain and other metabolic problems associated with existing medicines.

“One of the reasons CBD is exciting is because it is very well tolerated compared to the other anti-psychotics we have available,” Bhattacharyya of King’s College said.

“There is an urgent need for a safe treatment for young people at risk of psychosis.”

The Institute of Psychiatry, Psychology and Neuroscience at King’s College now plans a large 300-patient clinical trial to test the true potential of CBD as a treatment. Recruitment into the trial is expected to start in early 2019.

The latest findings underscore the complexity of the cocktail of chemicals found within the marijuana plant, at a time when cannabis laws are becoming more liberalized in many countries. 
Short link:

 

Email
 
Name
 
Comment's
Title
 
Comment
Ahram Online welcomes readers' comments on all issues covered by the site, along with any criticisms and/or corrections. Readers are asked to limit their feedback to a maximum of 1000 characters (roughly 200 words). All comments/criticisms will, however, be subject to the following code
  • We will not publish comments which contain rude or abusive language, libelous statements, slander and personal attacks against any person/s.
  • We will not publish comments which contain racist remarks or any kind of racial or religious incitement against any group of people, in Egypt or outside it.
  • We welcome criticism of our reports and articles but we will not publish personal attacks, slander or fabrications directed against our reporters and contributing writers.
  • We reserve the right to correct, when at all possible, obvious errors in spelling and grammar. However, due to time and staffing constraints such corrections will not be made across the board or on a regular basis.
Latest

© 2010 Ahram Online.